Elgebaly Ahmed, Radwan Ibrahim A I, AboElnas Mohamed M, Ibrahim Hamza H, Eltoomy Moutaz F M, Atta Ahmed A, Mesalam Hend A, Sayed Alaa A, Othman Amr A
Faculty of Medicine, Al Azhar University, Cairo, Egypt.
Ain Shams University, Faculty of Medicine, Cairo University, Cairo, Egypt.
J Gastrointestin Liver Dis. 2017 Mar;26(1):59-67. doi: 10.15403/jgld.2014.1121.261.ely.
Resveratrol is a potential treatment option for management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie restriction-like effects. We aimed to synthesise evidence from published randomized clinical trials (RCTs) about the efficacy of resveratrol in the management of NAFLD.
A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager Version 5.3 for windows. Subgroup analysis and sensitivity analysis were conducted.
Four RCTs (n=158 patients) were included in the final analysis. The overall effect estimates did not favor resveratrol group in terms of: serum ALT (MD -2.89, 95%CI [-15.66, 9.88], p=0.66), serum AST (MD -3.59, 95%CI [-13.82, 6.63], p=0.49), weight (MD -0.18, 95%CI [-0.92, 0.55], p=0.63), BMI (MD -0.10, 95 %CI [-0.43, 0.24], p=0.57), blood glucose level (MD -0.27, 95%CI [-0.55, 0.01], p=0.05), insulin level (MD -0.12, 95%CI [-0.69, 0.46], p=0.69), triglyceride level (MD 0.04, 95%CI [-0.45, 0.53], p=0.87), and LDL level (MD 0.21, 95%CI [-0.41, 0.83], p=0.51). Pooled studies were heterogeneous.
Current evidence is insufficient to support the efficacy of resveratrol in the management of NAFLD. Resveratrol does not attenuate the degree of liver fibrosis or show a significant decrease in any of its parameters.
白藜芦醇因其抗炎、抗氧化特性以及类似热量限制的作用，是治疗非酒精性脂肪性肝病（NAFLD）的一种潜在选择。我们旨在综合已发表的随机临床试验（RCT）中关于白藜芦醇治疗NAFLD疗效的证据。
使用相关关键词对PubMed、Scopus、Web of Science和Cochrane Central进行计算机文献检索。筛选符合条件的研究记录，并使用Windows版Review Manager 5.3提取和综合数据。进行亚组分析和敏感性分析。
最终分析纳入了4项RCT（n = 158例患者）。总体效应估计在以下方面对白藜芦醇组不利：血清谷丙转氨酶（MD -2.89，95%CI[-15.66，9.88]，p = 0.66）、血清谷草转氨酶（MD -3.59，95%CI[-13.82，6.63]，p = 0.49）、体重（MD -0.18，95%CI[-0.92，0.55]，p = 0.63）、体重指数（MD -0.10，95%CI[-0.43，0.24]，p = 0.57）、血糖水平（MD -0.27，95%CI[-0.55，0.01]，p = 0.05）、胰岛素水平（MD -0.12，95%CI[-0.69，0.46]，p = 0.69）、甘油三酯水平（MD 0.04，95%CI[-0.45，0.53]，p = 0.87）和低密度脂蛋白水平（MD 0.21，95%CI[-0.41，0.83]，p = 0.51）。汇总研究存在异质性。
目前的证据不足以支持白藜芦醇治疗NAFLD的疗效。白藜芦醇不会减轻肝纤维化程度，也未显示其任何参数有显著下降。
